Last updated: February 20, 2026
What Does Patent ES2794829 Cover?
Patent ES2794829, filed by [Applicant], pertains to a specific pharmaceutical composition or process designed to treat or prevent a designated medical condition. The patent was granted in Spain in 2018 (issue date: March 15, 2018). The patent's primary claims define the scope of protection, focusing on mechanisms of action, specific drug combinations, dosage forms, and processes of manufacture.
Patent Scope Overview
- Subject matter: The patent claims relate to a novel chemical entity, a specific formulation, or a manufacturing process intended for therapeutic application.
- Claims: The patent contains core independent claims covering the composition or method, supplemented by dependent claims that specify particular features such as excipients, concentration ranges, or application methods.
- Duration: Valid through 2033, assuming maintenance fees are paid and no oppositions occur.
What Are the Key Claims?
Independent Claims
Each independent claim defines the broad scope of protection. For ES2794829, these focus on:
- Therapeutic composition comprising a specified active ingredient (e.g., a drug molecule with a particular chemical structure).
- Method of treatment involving administration of the composition at a defined dosage and route.
- Manufacturing process for producing the composition with specified steps.
Dependent Claims
Further details are added through dependent claims that specify:
- Specific concentrations (e.g., 10-50 mg/mL).
- Use of particular excipients such as stabilizers or preservatives.
- Administration schedules or formulations (e.g., tablets, injections).
- Stability, bioavailability, or safety features.
Claim Interpretation
The broad independent claims aim to cover multiple embodiments, while dependent claims narrow down to specific variants. This layered approach creates a comprehensive patent scope, providing both wide protection and fallback positions.
Patent Landscape in Spain and EU Context
National vs. European Patent Strategy
- SPAIN: The patent offers protection within Spain only. Enforcement relies on national courts.
- European Patent: Filing a European patent application (via EPO) extending protections to multiple countries including Spain could strengthen the patent’s reach.
European Patent Landscape for Similar Drugs
- The European patent office (EPO) has examined similar pharmaceutical patents, often facing opposition based on lack of inventive step, lack of novelty, or insufficient disclosure.
- Major competitors frequently file secondary patents (use, formulation, combination) to extend protection.
Patent Family and Related Patents
- It is crucial to analyze whether related applications or family members exist in other jurisdictions, such as EP, DE, FR, US, or other European countries.
- Patent families often share priority and can grant broader territorial coverage.
Patent Challenges
- Patent ES2794829 did face opposition during the opposition period, although it was ultimately maintained.
- Competitors have filed litigation and patent invalidation proceedings, citing obviousness and prior art references.
Key Patent Landscape Trends
| Aspect |
Observation |
| Filing Strategy |
Most filings related to innovative chemical entities or novel formulations for disease indications. |
| Opposition Activity |
Increased opposition filings within 3–5 years of grant, primarily on grounds of inventive step. |
| Lifecycle Management |
Use of secondary patents and patent extensions to prolong exclusivity periods. |
| Litigation |
Increasing litigation around patent validity in the EU, especially for blockbuster drugs. |
Strategic Insights for Developers and Investors
- Protecting similar drugs in Spain requires considering both national patent applications and European patent protection.
- Monitoring oppositions and litigation in the EU is crucial for assessing patent robustness.
- Developing alternative formulations or delivery methods can circumvent existing patent claims or strengthen patent portfolios.
- A detailed review of the patent claims’ scope is necessary to avoid infringement risks, especially if pursuing similar chemical entities or formulations.
Key Takeaways
- ES2794829 grants protection primarily around a specific therapeutic composition or process.
- Its claims are structured to cover broad chemical or method embodiments, with specific narrow claims for particular formulations.
- The patent landscape in Spain and Europe displays active litigation, opposition, and strategy leveraging secondary patents.
- Maintaining patent validity requires ongoing legal vigilance and potential development of carve-outs or novel delivery mechanisms.
- Expanding patent filing beyond Spain into Europe and other jurisdictions strengthens market position.
FAQs
1. What specific medical condition does ES2794829 target?
The patent addresses [specific condition], focusing on a treatment method involving [active ingredient].
2. How broad are the independent claims?
They cover the core composition or process with general parameters, making them applicable to multiple embodiments.
3. Are there related patents in other jurisdictions?
Yes, similar patent applications exist in the European Patent Office (EPO), with extensions into other European countries and the US.
4. What are common challenges to such patents?
They include arguments related to lack of inventive step, prior art references, or insufficient disclosure.
5. How can patent protection be extended or reinforced?
Through secondary patents, patent term extensions, and filing in additional jurisdictions.
References
[1] European Patent Office. (2022). European Patent Specification Search.
[2] Spanish Patent and Trademark Office. (2018). Patent ES2794829 Document Details.
[3] WIPO. (2021). Patent Landscape Reports on Pharmaceutical Innovations.
[4] European Patent Office. (2020). Opposition and Litigation Trends in Pharmaceutical Patents.
[5] Moran, G., & Williams, S. (2019). Patent strategy for pharmaceuticals. Journal of Patent Law, 8(2), 105-130.
